New drug combination for advanced squamous lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial compares a new combination of drugs (one that targets cancer cells and another that boosts the immune system) against a standard chemotherapy plus immune therapy combination. The goal is to see if the new approach works better as a first treatment for advanced squamous lung cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have squamous non-small cell lung cancer that is locally advanced or has spread to other parts of the body.
- You have not had prior treatment for this lung cancer.
- You are willing to provide a tumor tissue sample.
- You are physically able to do light work (score 0 or 1 on a performance scale).
- You have adequate organ and heart function, and no major medical problems like uncontrolled infections or heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HB0025 combined with chemotherapy as the first treatment for advanced squamous non-small cell lung cancer that cannot be removed with surgery. It compares this combination to a standard treatment using another drug called pembrolizumab plus chemotherapy.
This trial tests a new combination of drugs (BL-B01D1 plus a bispecific antibody) against the current standard chemotherapy and immunotherapy. It aims to see if the new combination works better for people with advanced non-squamous non-small cell lung cancer who haven't had treatment before.
This trial tests a new drug (SCTB41) combined with chemotherapy for people with advanced squamous non-small cell lung cancer who have not had any prior treatment. It aims to see if this combination works better than standard therapy.
This trial tests a new combination treatment (BL-B01D1 plus a PD-1 inhibitor) for people with advanced lung cancer or nasopharyngeal cancer. It aims to see if the combination is safe and effective for patients whose cancer has not responded to earlier treatments.
This trial tests a new drug combination (BL-B01D1 plus immunotherapy) as a first treatment for people with advanced small cell lung cancer. It may be an option if you haven't had treatment yet and are healthy enough for chemotherapy.
This trial tests a new drug called BL-B01D1 combined with an immune therapy (tislelizumab) and sometimes chemotherapy against standard chemotherapy for esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if this new combination works better and is safer than current treatment.
Hear when a new Squamous Non-small-cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.